OnKure, Inc., a Boulder, CO-based the epigenetics-focused drug discovery and development company, completed a $7M Series A financing.
The round was led by Delian Capital with participation from existing and new investors including OnKure management.
The company intends to use the funds to accelerate its research and development activities.
Led by Tony Piscopio, co-founder, President & CEO, OnKure is a biopharmaceutical company focused on the discovery and development of targeted small molecule drugs to improve the outcomes of patients afflicted with cancer.
Its product candidates aim to treat cancer by targeting malignant cells and circulating lymphocytes, through alteration of the tumor microenvironment such that checkpoint inhibition is optimized, and through delaying kinase inhibitor resistance. OnKure’s most advanced programs target Class-1 histone deacetylase (HDAC) enzymes as well as HDAC6.